150 related articles for article (PubMed ID: 38035560)
1. Metformin Regulates the miR-205/VEGFA Axis in Renal Cell Carcinoma Cells: Exploring a Clinical Synergism with Tyrosine Kinase Inhibitors.
Krebs M; Kotlyar MJ; Fahl J; Janaki Raman S; Röhrig F; Marquardt A; Kübler H; Kneitz B; Schulze A; Kalogirou C
Urol Int; 2024; 108(1):49-59. PubMed ID: 38035560
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
4. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
[TBL] [Abstract][Full Text] [Related]
6. Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
Pasha M; Sivaraman SK; Frantz R; Agouni A; Munusamy S
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30909494
[TBL] [Abstract][Full Text] [Related]
7. Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma.
Velagapudi S; Schraml P; Yalcinkaya M; Bolck HA; Rohrer L; Moch H; von Eckardstein A
J Lipid Res; 2018 Nov; 59(11):2188-2201. PubMed ID: 30173145
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets.
Swearson S; Rataan AO; Eliason S; Amendt BA; Zakharia Y; Salem AK; Ho T; Rustum YM
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628416
[TBL] [Abstract][Full Text] [Related]
9. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
10. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.
Lukamowicz-Rajska M; Mittmann C; Prummer M; Zhong Q; Bedke J; Hennenlotter J; Stenzl A; Mischo A; Bihr S; Schmidinger M; Vogl U; Blume I; Karlo C; Schraml P; Moch H
Oncotarget; 2016 Nov; 7(48):78433-78447. PubMed ID: 27738339
[TBL] [Abstract][Full Text] [Related]
11. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
[TBL] [Abstract][Full Text] [Related]
12. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
13. miR-106a-5p Functions as a Tumor Suppressor by Targeting VEGFA in Renal Cell Carcinoma.
Ma J; Wang W; Azhati B; Wang Y; Tusong H
Dis Markers; 2020; 2020():8837941. PubMed ID: 33224312
[TBL] [Abstract][Full Text] [Related]
14. The VHL-dependent regulation of microRNAs in renal cancer.
Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
[TBL] [Abstract][Full Text] [Related]
15. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
16. Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression.
Kalogirou C; Schäfer D; Krebs M; Kurz F; Schneider A; Riedmiller H; Kneitz B; Vergho D
Urol Int; 2016; 96(1):106-15. PubMed ID: 26496641
[TBL] [Abstract][Full Text] [Related]
17. Control of Angiogenesis via a VHL/miR-212/132 Axis.
Lei Z; Klasson TD; Brandt MM; van de Hoek G; Logister I; Cheng C; Doevendans PA; Sluijter JPG; Giles RH
Cells; 2020 Apr; 9(4):. PubMed ID: 32325871
[TBL] [Abstract][Full Text] [Related]
18. MiR-212-5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15.
Deng JH; Zheng GY; Li HZ; Ji ZG
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10699-10707. PubMed ID: 31858538
[TBL] [Abstract][Full Text] [Related]
19. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
20. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
